Adding to evidence for IFN-I in autoimmune disease, recent phase III trials using an IFNAR1 monoclonal antibody blocking IFN-I activity (Anifrolumab) to treat SLE shows promising disease modifying activity (34). Here, IFNAR1 is linked to autoimmune disease.